4.4.1.20	2-benzoyl-5-(5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl)benzoic acid	i.e. TK04, competitive mode of binding versus leukotriene A4	197438	
4.4.1.20	2-benzoyl-5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]benzoic acid	potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells	226084	
4.4.1.20	2-methyl-5-(1-methylethyl)cyclohexa-2,5-diene-1,4-dione	-	59190	
4.4.1.20	5-[5-[(4-chlorophenyl)(cyclopropylmethyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid	compound at 6 mg/kg body weight reduces LTE4 levels in peritoneal lavage fluid by 88%and significantly decreases vascular permeability in vivo. Potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells	226086	
4.4.1.20	5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid	tandem benzophenone amino pyridine inhibitor	226085	
4.4.1.20	5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid	potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells	226085	
4.4.1.20	aspirin	blocks the STAT6-dependent interleukin-4-inducible expression of LTC4S	3100	
4.4.1.20	bovine serum albumin	5 mg, 45% inhibition	274	
4.4.1.20	Co2+	-	23	
4.4.1.20	cysteinyl-leukotriene	-	129863